Table 1

Demographic, psychopathological and clinical characteristics of study participants

Group; mean ± SD*
CharacteristicSchizophrenia, n = 27Control, n = 25Statistical testp value
Age, yr31.9 ± 7.133.0 ± 9.7U = 322.000.78
Sex, female:male9:189:16χ2 = 0.040.81
Education, yr12.2 ± 3.012.4 ± 3.6U = 334.000.95
Duration of illness, yr9.2 ± 6.6
Age of onset, yr22.7 ± 6
Chlorpromazine equivalents, mg/d491.3 ± 349.5
BNSS score
 Apathy (motivation and pleasure)14.8 ± 6.8
 Diminished expression9.8 ± 7.4
SANS score§
 Apathy12.8 ± 5.1
 Diminished expression12.6 ± 10.7
PANSS score
 Positive6.6 ± 2.5
 Negative13.6 ± 5.2
 Disorganized4.5 ± 2.2
 Excited5.1 ± 1.5
 Depressed5.1 ± 2.2
 Total49.4 ± 11.2
CDSS total score1.5 ± 2.2
GAF score56.9 ± 9.6
PSP total score56.4 ± 9.9
Cognition (Composite Cognitive Ability)**0.61 ± 0.890 ± 0.53t = 3.00.010
MWT IQ25.9 ± 5.827.6 ± 4.0t = 1.20.23
  • BNSS = Brief Negative Symptom Scale; CDSS = Calgary Depression Scale for Schizophrenia; GAF = Global Assessment of Functioning; MWT IQ = Multiple Word Test Intelligence Quotient; PANSS = Positive and Negative Syndrome Scale; PSP = Personal and Social Performance Scale; SANS = Scale for the Assessment of Negative Symptoms; SD = standard deviation.

  • * Unless otherwise indicated.

  • All patients were receiving atypical antipsychotics at the time of testing.

  • Potential group differences were investigated using 2-sample t tests for continuous and χ2 tests for categorical data. For non-normally distributed data Mann–Whitney U tests were applied.

  • § Apathy includes avolition/apathy and anhedonia/asociality; diminished expression includes affective flattening or blunting and alogia.

  • Positive factor = P1, P3, P5, G9; negative factor = N1, N2, N3, N4, N6, G7; disorganized factor = P2, G5, N11; excited factor = P4, P7, G8, G14; depressed factor = G2, G3, G6.

  • ** Cognition data have been z-transformed based on the data of the control group for each test separately. The Composite Cognitive Ability score was computed as the mean of the z-transformed test scores at the participant level.